Ï Ä.Ì. åîïìïëïãåßôáé...

Boy Ç éóôïñßá ìïõ åßíáé ëßãï-ðïëý ßäéá ìå áñêåôþí üóùí Ý÷ïõí ãñÜøåé åäþ.

¸÷ïõìå ðïëëÜ êïéíÜ. Êé åãþ êÜðùò Ýôóé óêÝöôçêá íá ãñÜøù ôç äéêÞ ìïõ éóôïñßá.

Åßìáé 26 ÷ñïíþí êáé Ýìáèá ðùò åßìáé ïñïèåôéêüò ìüëéò ðñéí áðü ìéá åâäïìÜäá.

Ìéá öïñÜ áðåñéóêåøßáò Þôáí áñêåôÞ ãéá íá ôçí ðáôÞóù êáé ãéá üóïõò ðéóôåýïõí üôé åäþ óôçí ÅëëÜäá äåí êéíäõíåýåéò ðïëý, Ý÷ù íá ðù ðùò åãþ ôï Ýðáèá öõóéêÜ åäþ. ÐïõèåíÜ áëëïý.

Ôçí ðÜôçóá ìå ìüíï ìéá öïñÜ ÷ùñßò ðñïöõëáêôéêü, ìå Ýíáí ðïëý ìéêñüôåñü ìïõ óôçí çëßêéá. ÊÜðïéïé ößëïé ìïõ åß÷áí ðåé ôüôå üôáí ôïõò åéðá ðùò Ýêáíá ìáëáêéá êáé ôïí Üöçóá íá êÜíïõìå óåî ÷ùñßò ðñïöõëáêôéêü: «¢íôå ñå, ìçí áíçóõ÷åßò. Áõôü åßíáé ó÷åäüí ìùñü áêüìá...».
Ðïëëïß èåùñïýí ðùò åßíáé èÝìá çëéêéáò êáé üôé áí ðáò ìå êÜðïéïí ìéêñüôåñï, äåí Ý÷åéò öüâï.

¸êáíá ôñßá åðáíáëçðôéêÜ ôåóô ìÝ÷ñé ôåëéêÜ íá äéáðéóôþóù üôé Ý÷ù ìïëõíèåß ìå ôïí HIV.
Óôï éäéùôéêü åñãáóôÞñéï üðïõ Ýêáíá ôçí ðñþôç åîÝôáóç ãéá HIV Þôáí ðïëý äéáêñéôéêïß. Ìïõ åßðáí üôé ôï áðïôÝëåóìá Þôáí ïñéáêÜ èåôéêü êáé üôé ÷ñåéáæüôáí áðáñáßôçôá åðéâåâáßùóç.
Ôþñá ðüóï ïñéáêü Þ îåêÜèáñï Þôáí, Ýíáò Èåüò ôï îÝñåé.

Óôï äçìüóéï íïóïêïìåßï üðïõ ìå Ýóôåéëáí ãéá ðåñáéôÝñù åîåôÜóåéò, ïé íïóïêüìåò êÜèå öïñÜ ðïõ ìå êïßôáãáí Þôáí óáí íá ìïõ ôï óéãïõñåýïõí.

¸êáíáí íåýìáôá ðïõ êáé êáëÜ íüìéæáí üôé äåí Ýâëåðá.
ØéèõñéóôÝò óõíïìéëßåò ôçí þñá ðïõ ðåñéìåíá. ÊÜðïéïé óõíáäåëöïß ôïõò ðïõ Ýâãáéíáí íá äïõí êáé êáëÜ áí êïõíéïýíôáé ïé âÜñêåò.
Äåí Þîåñá åáí Ýðñåðå íá êëÜøù Þ íá ãåëÜóù ìå áõôÞ ôçí êáôÜóôáóç.
Áðü ôçí Üëëç âÝâáéá ìðïñåß üðïéïò Ý÷åé ôç ìýãá íá ìõãéÜæåôáé, üðùò ëÝíå...

Ìüëéò Ýêáíá ôï äåýôåñï ôåóô ãéá HIV, Üñ÷éóá íá øÜ÷íù óôï ßíôåñíåô ðëçñïöïñßåò ãéá ôï AIDS áëëÜ äõóôõ÷þò äåí âñÞêá ðïëëÝò ó÷åôéêÝò éóôïóåëßäåò áðü ÅëëÜäá, ïðüôå Ýöôáóá ãñÞãïñá óå áõôÞí åäþ.

Eßìáé áñêåôÜ áéóéüäïîïò êáé åëðßæù ïôé áõôÜ ðïõ èÝëù íá êÜíù óôï ìÝëëïí, èá êáôáöÝñù ôåëéêÜ íá ôá êÜíù. ¸óôù êáé áí ðáñïõóéáóôïýí êÜðïéåò äõóêïëßåò óôï ìÝëëïí ëüãù ôçò áóèÝíåéÜò ìïõ.

¹èåëá íá ðù ðùò ôï íá åßìáé óå ìéá ó÷åôéêÜ Þñåìç øõ÷ïëïãéêÞ êáôÜóôáóç - ïýôå ðïëý êáëÜ, áëëÜ ïýôå êáé ðïëý óôåíá÷ùñçìÝíïò ìå êëÜììáôá êáé ôÝôïéá (åêôüò ôçò ðñþôçò ìÝñáò ðïõ ôï Ýìáèá) - âïÞèçóáí ïé éóôïñßåò ðïõ äéÜâáóá åäþ.

Íéþèù üôé åßìáé äõíáôüò ãéá íá ôï áíôéìåôùðßóù êáé åëðßæù ðùò ìå ôçí âïÞèåéá ôùí ãéáôñþí, üëá èá ðÜíå êáëÜ.

Ç æùç óõíå÷ßæåôáé... óôï ìÜîéìïõì!




... 'Aëëåò éóôïñßåò ...



Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Another step towards closing the paediatric treatment gap

Expanding access to antiretroviral therapy (ART) and reducing new HIV acquisitions among women has led to a marked decline in vertical HIV transmission over the past decade. Nevertheless, in 2023 alone, an estimated 120 000 children aged 0–14 years acquired HIV globally, with the vast majority living in Africa.1 Without treatment, over half of infants and young children with perinatally acquired HIV die before their second birthday.2 Early diagnosis and timely linkage to care are therefore essential to reducing morbidity and mortality.

Deworming of filariasis and reduction of HIV incidence

In sub-Saharan Africa, lymphatic filariasis and HIV infection are two major public health problems that often coexist.1 For several decades, scientists have been exploring the negative impact of helminth infections, including the filarial nematode Wucheria bancrofti, on HIV acquisition and pathogenesis.1–3 Immunological studies have tried to validate the anecdotal, but biologically plausible, theory that modulatory effects of helminths such as W bancrofti can affect HIV infection.3–5 However, some of these studies were inconclusive, and many were characterised by two common flaws, cross-sectional design1 or small sample size,3 weakening the strength of the evidence.

Modelling study shows staggering impact of HIV funding cuts

The global AIDS response has seen substantial reductions in HIV incidence and number of deaths.1 The greatest improvements have been recorded in sub-Saharan Africa, the region with the worst HIV burden. Many of the advances are attributed to international funding of national programmes within sub-Saharan Africa. International contributions were estimated to be 41% of total HIV expenditure in low-income and middle-income countries (LMICs) in 2023.1 Over the last 5–10 years there have been reported declines in HIV funding from both domestic contributions and non-US international funders.

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò

ÔçëåöùíéêÞ ãñáììÞ ãéá ôï HIV/AIDS

210-7222222

ÄåõôÝñá - ÐáñáóêåõÞ
09:00 - 21:00